{
  "schema_version": "chamgap-public-criteria-1.0",
  "title": "Oral curcumin or curcuminoid supplementation × Reduction of systolic blood pressure in adults with metabolic risk",
  "language": "en",
  "translation_date": "2026-10-24",
  "criteria_version": "1.0",
  "criteria_date": "2026-10-06",
  "condition_origin": "Chamgap's own application conditions",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.",
      "review_level": "Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed."
    }
  ],
  "status_dictionary": {
    "Partly verified": "Partial information from the stored summary is linked; detailed originals and content review remain incomplete.",
    "Unverified": "Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.",
    "Review incomplete": "Review of existing content remains incomplete.",
    "Met": "This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.",
    "Not reported": "Unreported within material actually read. Unread external material is not relabeled as unreported.",
    "Inaccessible": "This means actual access failure. External access was not attempted in this work, so this state was not assigned.",
    "Not applicable": "Used only with an application exception and reason based on the question scope.",
    "Conflicting data": "This requires actual comparison of materials; no new conflict judgment was made in this work.",
    "Insufficient evidence for the conditions": "This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade."
  },
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Evidence condition",
      "question": "Which systolic-blood-pressure question is addressed?",
      "needed": "Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk",
      "role": "Required",
      "role_reason": "Material on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Oral curcumin/curcuminoid supplementation and office SBP change in adults with metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original eligibility criteria and endpoint tables specifying the same population, formulation, comparator and office SBP are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N02",
      "question_type": "Evidence condition",
      "question": "Which formulations were pooled, and do they match individual products?",
      "needed": "Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations",
      "role": "Required",
      "role_reason": "Material on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Original-trial tables separating conventional curcumin, nano/micellar, phytosomal and piperine-combination formulations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Actual formulations, absorption enhancers, standardized amounts and product information for included trials are unavailable; efficacy or equivalence of an individual product is not established. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N03",
      "question_type": "Evidence condition",
      "question": "Which doses and administration frequencies were compared?",
      "needed": "Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies",
      "role": "Required",
      "role_reason": "Material on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific active-curcumin/curcuminoid amounts, total product amounts and administration frequencies must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original amount/dose/adherence tables are needed. The phrase dose response in the meta-analysis title does not establish an optimum dose. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N04",
      "question_type": "Evidence condition",
      "question": "How are duration and outcome timepoints arranged?",
      "needed": "Trial-specific exposure durations and final SBP timepoints",
      "role": "Required",
      "role_reason": "Material on Trial-specific exposure durations and final SBP timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific exposure durations and final SBP timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Trial-specific durations, measurement schedules and original extracted values by duration group are needed. Long-term persistence and post-discontinuation effects remain unverified. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N05",
      "question_type": "Evidence condition",
      "question": "Do the included adults share the same risks and diagnoses?",
      "needed": "Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk",
      "role": "Required",
      "role_reason": "Material on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Composition by diagnosis/baseline risk among adults with hypertension, prehypertension or metabolic risk must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original-trial tables by diagnosis, baseline SBP, age, comorbidities and eligibility/exclusion criteria are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N06",
      "question_type": "Evidence condition",
      "question": "Was the comparator placebo or control management?",
      "needed": "Trial-specific placebo/control management and common-care arrangements",
      "role": "Required",
      "role_reason": "Material on Trial-specific placebo/control management and common-care arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific placebo/control management and common-care arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Trial-specific material separating placebo ingredients, blinding, shared dietary/exercise management and additional interventions is needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N07",
      "question_type": "Evidence condition",
      "question": "How do concomitant blood-pressure medicines and lifestyle management differ?",
      "needed": "Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups",
      "role": "Required",
      "role_reason": "Material on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Baseline blood-pressure medicines, changes, diet/exercise management and whether these were shared across groups must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original-trial records on medicine doses/changes, lifestyle management, rescue medicines and adherence are needed. Efficacy is not separated as the supplement-only effect. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N08",
      "question_type": "Evidence condition",
      "question": "What included-material unit does the reported 17 represent?",
      "needed": "Review inclusion lists and study-to-report links",
      "role": "Required",
      "role_reason": "Material on Review inclusion lists and study-to-report links is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Review inclusion lists and study-to-report links must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Links among included articles, registrations, duplicate reports and multiple arms are needed. Reported scope remains distinct from verified unique-trial counts. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N09",
      "question_type": "Evidence condition",
      "question": "What denominator does 1,377 people represent?",
      "needed": "Trial-specific allocation, analysis, completion and SBP-endpoint denominators",
      "role": "Required",
      "role_reason": "Material on Trial-specific allocation, analysis, completion and SBP-endpoint denominators is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific allocation, analysis, completion and SBP-endpoint denominators must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Trial/group-specific randomized, analyzed and completed denominators, with participant-overlap information, are needed. The final unique-participant total remains null. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N10",
      "question_type": "Evidence condition",
      "question": "Can review reports be linked to original-trial families?",
      "needed": "Included-trial identifiers and study-family links for the Hadi review",
      "role": "Required",
      "role_reason": "Material on Included-trial identifiers and study-family links for the Hadi review is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Included-trial identifiers and study-family links for the Hadi review must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Articles, registrations and additional reports for included trials, with the review extraction table, are needed. Shared trials and reused samples remain unverified. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N11",
      "question_type": "Evidence condition",
      "question": "In which units is the overall SBP effect reported?",
      "needed": "Overall office-SBP WMD, units and original comparison arrangements",
      "role": "Required",
      "role_reason": "Material on Overall office-SBP WMD, units and original comparison arrangements is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Overall office-SBP WMD, units and original comparison arrangements must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original pooling tables, extracted values, weights, analysis models and change/final-value distinctions are needed. New estimates, conversions and clinical numerical calculations are not produced. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N12",
      "question_type": "Evidence condition",
      "question": "What is the scope of the original CI and null interpretation?",
      "needed": "Original 95% CI and source of SBP-importance criteria",
      "role": "Required",
      "role_reason": "Material on Original 95% CI and source of SBP-importance criteria is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Original 95% CI and source of SBP-importance criteria must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Unread original analysis tables and prespecified importance/equivalence criteria are needed. Equivalence for all formulations/populations or a new D verdict is not certified here. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N13",
      "question_type": "Evidence condition",
      "question": "How are I² and between-trial differences retained?",
      "needed": "Overall heterogeneity and explanations by formulation, diagnosis, dose and duration",
      "role": "Required",
      "role_reason": "Material on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Overall heterogeneity and explanations by formulation, diagnosis, dose and duration must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original heterogeneity tables, extracted values, model/sensitivity analyses and prediction intervals are needed. I² alone does not establish equal results across formulations. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N14",
      "question_type": "Evidence condition",
      "question": "Is office SBP measurement distinguished from other blood-pressure measures?",
      "needed": "Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions",
      "role": "Required",
      "role_reason": "Material on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Office-SBP equipment, repetitions, timing, assessors and original endpoint definitions must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Trial-specific measurement procedures, assessor blinding and repeated-measurement/averaging rules are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N15",
      "question_type": "Evidence condition",
      "question": "Are change values, baseline adjustment and analysis timepoints aligned?",
      "needed": "SBP change versus final/baseline-adjusted values and intended analysis populations",
      "role": "Required",
      "role_reason": "Material on SBP change versus final/baseline-adjusted values and intended analysis populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on SBP change versus final/baseline-adjusted values and intended analysis populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original extraction tables, analysis plans, baseline values, variance handling, endpoint timepoints and duplicate-timepoint selection rules are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N16",
      "question_type": "Evidence condition",
      "question": "What is known about allocation and blinding in original trials?",
      "needed": "Trial-specific randomization, concealment and participant/assessor blinding",
      "role": "Required",
      "role_reason": "Material on Trial-specific randomization, concealment and participant/assessor blinding is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific randomization, concealment and participant/assessor blinding must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original-trial methods, registration/protocols and the review's individual risk-assessment bases are needed. Official RoB2 findings are not generated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N17",
      "question_type": "Evidence condition",
      "question": "What is known about attrition, missingness and outcome selection?",
      "needed": "Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting",
      "role": "Required",
      "role_reason": "Material on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial-specific attrition reasons, missing-data handling, analysis sets and selective reporting must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Group flow diagrams, analysis denominators, missing-data handling, all SBP timepoints and registration-to-report comparisons are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N18",
      "question_type": "Evidence condition",
      "question": "Is the prespecified hierarchy of overall SBP and subgroups verified?",
      "needed": "Prespecified overall-SBP analysis and women/duration subgroup plans",
      "role": "Required",
      "role_reason": "Material on Prespecified overall-SBP analysis and women/duration subgroup plans is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Prespecified overall-SBP analysis and women/duration subgroup plans must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Review registration, protocols/SAPs with primary-endpoint/subgroup/multiplicity plans, and original-trial prespecified endpoint hierarchies, are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N19",
      "question_type": "Evidence condition",
      "question": "Are signals in women distinguished from the overall adult effect?",
      "needed": "Women-subgroup effects, intervals, denominators and interaction tests",
      "role": "Supplementary",
      "role_reason": "Material on Women-subgroup effects, intervals, denominators and interaction tests is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Women-subgroup effects, intervals, denominators and interaction tests must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original sex-subgroup tables, prespecification, interactions and included-trial counts are needed. The overall −0.06 mmHg is not copied as a women-only estimate. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N20",
      "question_type": "Evidence condition",
      "question": "Are signals in the subgroup lasting at least 12 weeks distinguished from all durations?",
      "needed": "Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations",
      "role": "Supplementary",
      "role_reason": "Material on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Trial composition, effects, intervals and denominators for durations of at least 12 weeks versus shorter durations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original duration-group tables, prespecification, other formulation/population differences accompanying duration, and interaction material are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N21",
      "question_type": "Evidence condition",
      "question": "Is a DBP reduction kept from becoming an SBP success?",
      "needed": "Separate SBP/DBP endpoints, denominators and timepoints",
      "role": "Supplementary",
      "role_reason": "Material on Separate SBP/DBP endpoints, denominators and timepoints is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Separate SBP/DBP endpoints, denominators and timepoints must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original DBP results and endpoint hierarchy address a separate question. DBP estimates and grades are not merged into these SBP rows. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N22",
      "question_type": "Evidence condition",
      "question": "Are mechanistic endpoints such as endothelial function kept separate?",
      "needed": "Distinguishing endothelial function/biomarkers from SBP change",
      "role": "Supplementary",
      "role_reason": "Material on Distinguishing endothelial function/biomarkers from SBP change is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Distinguishing endothelial function/biomarkers from SBP change must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Separate definitions, trials and original results for mechanistic endpoints are needed. Mechanistic improvement is not relabeled as an SBP or clinical-event effect. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N23",
      "question_type": "Evidence condition",
      "question": "Does dose-response meta-analysis establish direct dose comparisons?",
      "needed": "Distinguishing within-trial direct dose comparisons from between-trial dose-response models",
      "role": "Supplementary",
      "role_reason": "Material on Distinguishing within-trial direct dose comparisons from between-trial dose-response models is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Distinguishing within-trial direct dose comparisons from between-trial dose-response models must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Trial-specific doses, effects, covariates, model/sensitivity analyses and direct dose trials are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N24",
      "question_type": "Evidence condition",
      "question": "Is independent replication within a formulation verified separately?",
      "needed": "Unique trials and independent teams sharing formulation, population, comparator and timepoint",
      "role": "Required",
      "role_reason": "Material on Unique trials and independent teams sharing formulation, population, comparator and timepoint is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Unique trials and independent teams sharing formulation, population, comparator and timepoint must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original included-trial links, funding/authors and product information are needed. Mixed-formulation pooling alone does not establish independent replication for a particular formulation. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N25",
      "question_type": "Evidence condition",
      "question": "Are clinical events and replacement of blood-pressure medicines separate questions?",
      "needed": "Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines",
      "role": "Supplementary",
      "role_reason": "Material on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Direct material distinguishing an SBP surrogate from cardiovascular events and stopping/replacing medicines must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Direct research on cardiovascular events or stopping/replacing medicines is not verified in this material. Prevention, treatment or replacement effects are not added here. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N26",
      "question_type": "Evidence condition",
      "question": "Are four routes of company involvement kept separate?",
      "needed": "Review/trial funding, product support, employee authorship and COI",
      "role": "Required",
      "role_reason": "Material on Review/trial funding, product support, employee authorship and COI is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Review/trial funding, product support, employee authorship and COI must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Original funding, product provision, author affiliations and COI disclosures for the review and original trials are needed. Non-commercial researchers do not establish absence of company involvement in every trial. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N27",
      "question_type": "Evidence condition",
      "question": "Are harm-collection methods known?",
      "needed": "Adverse-event definitions, active/passive collection, durations and group-specific classification",
      "role": "Supplementary",
      "role_reason": "Material on Adverse-event definitions, active/passive collection, durations and group-specific classification is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Adverse-event definitions, active/passive collection, durations and group-specific classification must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Included-trial harm methods, event tables, withdrawals and severity records are needed. Unread material is not labeled as no harm. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N28",
      "question_type": "Evidence condition",
      "question": "What are harm denominators and exposure durations?",
      "needed": "Group-specific safety denominators, actual dosing, exposure durations and harm analyses",
      "role": "Supplementary",
      "role_reason": "Material on Group-specific safety denominators, actual dosing, exposure durations and harm analyses is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Group-specific safety denominators, actual dosing, exposure durations and harm analyses must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Safety sets, exposure amounts/time, group-specific event counts and discontinuation records are needed. Incidence is not calculated. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N29",
      "question_type": "Evidence condition",
      "question": "What evidence level underlies concomitant hypotension/interaction precautions?",
      "needed": "Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons",
      "role": "Supplementary",
      "role_reason": "Material on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Concomitant blood-pressure medicines, event timing, alternative causes and direct comparisons must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Medicine types/changes, event timing, comparators, rechallenge and alternative-cause material are needed. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N30",
      "question_type": "Evidence condition",
      "question": "Are long-term, rare-event and vulnerable-population harms verified?",
      "needed": "Harm material on long exposure, rare events and vulnerable populations",
      "role": "Supplementary",
      "role_reason": "Material on Harm material on long exposure, rare events and vulnerable populations is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Harm material on long exposure, rare events and vulnerable populations must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Long-term follow-up, vulnerable populations, independent harm reports and exposure/denominators are needed. These harms are not newly investigated or established here. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N31",
      "question_type": "Evidence condition",
      "question": "Is actual reading scope distinguished from original-source links?",
      "needed": "Distinguishing stored summary, abstract, full text, registration and protocols/SAPs",
      "role": "Required",
      "role_reason": "Material on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Distinguishing stored summary, abstract, full text, registration and protocols/SAPs must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: External original material remains unread until acquired and reviewed. A URL does not establish reading, accessibility or fulfillment of conditions. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N32",
      "question_type": "Evidence condition",
      "question": "How are historical English corrections and remaining generic wording retained?",
      "needed": "Original Korean/English material and targets/limits of the 2026-09-14 correction",
      "role": "Supplementary",
      "role_reason": "Material on Original Korean/English material and targets/limits of the 2026-09-14 correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Original Korean/English material and targets/limits of the 2026-09-14 correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: Historical corrected English and external papers are not newly compared here. The original correction is not relabeled as completed current content QA or certified original-paper reading. This records needed materials; no new research was executed."
    },
    {
      "item_id": "N33",
      "question_type": "Evidence condition",
      "question": "Are original grade, axes, dates and new preparation distinguished?",
      "needed": "Original D30, Caution, axes, evidence date and correction",
      "role": "Required",
      "role_reason": "Material on Original D30, Caution, axes, evidence date and correction is needed to connect the relevant formulation, population, comparator, SBP measurement/timepoint, report/trial, denominator, overlap or harm scope.",
      "application_exception": "Review reports remain distinct from unique original trials and participants. Overall SBP, women/duration subgroups, DBP and endothelial function remain separate; scope is not extended to product-specific effects, equivalence, optimum doses, medicine replacement, clinical-event prevention or overall safety.",
      "criterion": "Original records on Original D30, Caution, axes, evidence date and correction must link to reports, trials, denominators, formulations, populations, SBP measurements and timepoints, distinguishing stored information from what remains unverified.",
      "basis": "Existing principles distinguish formulation, population, comparator, measurement/timepoint, reports/trials, denominators, overlap, support and harms in the retained SBP record.",
      "condition_origin": "These existing conditions are linked to the retained SBP question. They explain material gaps without establishing new preregistration, official assessment or independent clinical validation.",
      "proposed_research": "Material needed: New material and verdict changes are handled through separate review and events. The original verdict date is not relabeled as a current search-end or external-reading date. This records needed materials; no new research was executed."
    }
  ]
}